Skip to main content
    O

    Oramed Pharmaceuticals Inc (ORMP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.87
    -0.03 (-0.77%)

    Market Cap: $169.59M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Oramed Pharmaceuticals Inc (ORMP) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Oramed Pharmaceuticals (ORMP) has a market cap of $169.59M. Revenue fell 100.00% over the last 12 months from the 12 months before. Its dividend yield is 6.46%.

    Total Valuation

    Market Cap$169.59M
    Latest price (Nov 17, 2026)$3.87

    Key Dates

    The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Jan 16, 2026.

    Next Earnings DateMar 24, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Last Ex-Dividend DateJan 16, 2026
    Last Payment DateJan 26, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.21% in the quarter ended Sep 30, 2026 and grew 2.56% a year over 2 years.

    Shares Outstanding43.02M
    Shares Change (YoY)+0.56%
    Shares Change (QoQ)+1.21%
    Share Count Growth (2Y CAGR)+2.56%

    Valuation Ratios

    P/E Ratio4.2x
    Forward P/E0.8x
    P/B Ratio0.5x

    Valuation history and multiples

    Price Statistics

    The stock is up 77.38% over 52 weeks and trades 10.42% below its 50-day average.

    Beta (1Y)1.18
    52-Week Change+77.38%
    1-Month Change-4.68%
    3-Month Change-19.21%
    6-Month Change-10.62%
    5-Year Change-82.44%
    10-Year Change-38.10%
    Total Return (1Y)+88.83%
    Total Return (3Y CAGR)+26.32%
    Total Return (5Y CAGR)-31.64%
    Return vs SPY (1Y)+54.42%
    Max Drawdown (1Y)-30.52%
    Max Drawdown (3Y)-44.13%
    Sharpe Ratio (1Y)0.96
    Correlation with SPY (1Y)0.31
    50-Day Average$4.32
    200-Day Average$4.06
    52-Week Range$2.22 to $5.47
    RSI (14 Days)41.8
    Average Volume (20 Days)124.21K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.07x current liabilities.

    Current Ratio6.07x
    Quick Ratio6.07x
    Interest Coverage1.99x

    Returns and Efficiency

    Return on equity is 42.73% over the last 12 months, against a 5-year average of -4.34%.

    Return on Equity (ROE)42.73%
    Return on Assets (ROA)36.14%
    ROE (5Y Average)-4.34%
    ROA (5Y Average)-4.55%
    ROIC (5Y Average)-4.23%

    Taxes

    Income tax took 23.38% of pretax income over the last 12 months.

    Income Tax (TTM)$44.22M
    Effective Tax Rate23.38%

    Scores

    ORMP has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$60.00K
    Operating Income-$16.20M
    Pretax Income$189.10M
    Net Income$144.88M
    Reported EPS (TTM)$0.91

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 84.58% of the $400.92M in total assets.

    Cash and Equivalents$28.93M
    Working Capital$47.93M
    Shareholder Equity$339.09M
    Book Value Per Share$7.88
    Total Assets$400.92M
    Total Liabilities$61.83M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $213.00K of capital spending, operating cash flow left -$3.37M of free cash flow.

    Operating Cash Flow-$3.15M
    Capital Expenditures$213.00K
    Free Cash Flow-$3.37M
    FCF Per Share-$0.08
    Depreciation and Amortization$121.00K
    Dividends Paid$31.73M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Revenue fell 9.55% a year over 3 years.

    Revenue Growth (3Y CAGR)-9.55%
    Revenue Growth (5Y CAGR)-5.90%
    Book Value Per Share Growth (2Y CAGR)+10.32%
    Tangible Book Per Share Growth (2Y CAGR)+10.32%

    Revenue and profit by year

    Dividends and Yields

    ORMP pays out 7.42% of earnings as dividends.

    Dividend Per Share (Annual)$0.25
    Dividend Yield6.46%
    Payout Ratio7.42%
    Earnings Yield23.81%
    FCF Yield-2.02%
    Shareholder Yield19.06%

    Stock Splits

    The last split was a 1-for-12 reverse split on Jan 23, 2013.

    Last Split DateJan 23, 2013
    Split TypeReverse split
    Split Ratio1:12

    Analyst Forecast

    Consensus estimates put EPS growth at 198.00% a year over the next fiscal year.

    EPS Growth Forecast (1Y CAGR)+198.00%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ORMP

    What is ORMP's market cap?

    Oramed Pharmaceuticals has a market cap of $169.59M.

    What is ORMP's P/E ratio?

    Oramed Pharmaceuticals has a trailing P/E ratio of 4.2x and a forward P/E of 0.8x.

    How many shares of ORMP are outstanding?

    Oramed Pharmaceuticals has 43.02M shares outstanding. The count is up 0.56% from a year earlier.

    Does ORMP pay a dividend?

    Yes. Oramed Pharmaceuticals pays $0.25 a share a year, a dividend yield of 6.46%.